摘要
目的探讨化疗前18F-脱氧葡萄糖(18F-FDG)标准摄取值(SUV)对晚期非小细胞肺癌(NSCLC)疗效评价及与临床因素的关系。方法 21例晚期NSCLC患者化疗前行PET-CT检查,比较不同性别、年龄、肿瘤原发灶大小、病理类型、组织分化程度、转移部位多少等对SUV的影响,并探讨原发灶SUV与化疗疗效的关系。结果肿瘤原发病灶<3cm者的SUV水平低于≥3cm组(P<0.05);转移病灶数>2处者其SUV水平明显高于≤2处者(P<0.05);肿瘤组织高分化和中分化者SUV水平明显小于低分化和未分化者(P<0.05);不同性别、年龄、病理类型间SUV水平差异无统计学意义(P>0.05)。化疗有效者治疗前SUV水平低于化疗无效者(P<0.05)。结论化疗前18F-FDG SUV水平与原发病灶大小、分化程度、转移部位多少有关,治疗前SUV低水平者更可能从化疗中获益。
Objective To investigate the clinical value of 18-fluorodeoxyglucose（18 F-FDG） standard uptake value（SUV） before chemotherapy in patients with advanced non-small cell lung cancer and to analyze the relationship with clinical characteristics.Methods Twenty-one patients with histologically proven NSCLC had 18 F-FDG PET-CT scans before chemotherapy.The correlations between SUV of 18 F-FDG and primary tumor size,pathological type,cell differentiation and response rate were analyzed.Results There were significant differences in SUV according to primary tumor size（3cm versus ≥3cm） 、cell differentiation（well and moderate differentiation group versus poor and undifferentiation group）、metastasis（2sites versus ≤2 sites,P0.05）,while no difference was observed in different age、gender and pathological types.The levels of SUV in patients respond to chemotherapy were lower than in nonresponder（P0.05）.Conclusions The level of 18 F-FDG SUV is relative to primary tumor size、cell differentiation and metastasis,patients with lower levels of SUV were more likely to respond to chemotherapy.
出处
《中国肿瘤临床与康复》
2012年第6期481-483,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
